Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT03297775
Recruiting
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the devel... Read More
Gender:
All
Ages:
Between 45 years and 90 years
Trial Updated:
11/28/2023
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +113 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
NCT04911127
Recruiting
The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California
Conditions: Rheumatoid Arthritis, Cannabis
Register for Updates
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
NCT06073093
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Altoona Center For Clinical Research Site Number : 8400002, Duncansville, Pennsylvania +1 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
NCT06031415
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The primary objectives of this study are to assess the safety and tolerability of multiple ascending subcutaneous (SC) doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple SC doses of GS-0272, in participants with RA or SLE.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2023
Locations: Altoona Center for Clinical Research, Duncansville, Pennsylvania +2 locations
Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Register for Updates
Insignia™ Hip Stem Outcomes Study
NCT05144191
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Reno Orthopedic Center Foundation, Reno, Nevada +1 locations
Conditions: Hip Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Osteoarthritis, Femoral Neck Fractures, Trochanteric Fractures, Surgery
Register for Updates
Genetic and Social Network Correlates of Rheumatoid Arthritis Outcomes in Hispanic Populations: A Prospective Study
NCT05457816
Recruiting
Background: Rheumatoid arthritis (RA) is more severe in Hispanic people. Genetics plays a role. But social issues may also lead to more severe RA in Hispanics. Some Hispanics may not seek help for early symptoms. Support from family and friends may persuade people to seek treatment earlier. Researchers want to learn more about how social factors affect RA in Hispanics. Objective: This natural history study will explore genetic and social factors related to RA in Hispanic families. Eligibilit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: National Human Genome Research Institute (NHGRI), Bethesda, Maryland +1 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Cemented vs Cementless Persona Keel RCT
NCT05630053
Recruiting
The main objective of this study is to evaluate the safety, performance, and clinical benefits of the Persona Keel cementless and cemented knee.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Centura Health, Westminster, Colorado +4 locations
Conditions: Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis, Polyarthritis, Avascular Necrosis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee
Register for Updates
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Denver Hip & Knee, Inc., Parker, Colorado +11 locations
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Register for Updates
A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis
NCT05197036
Recruiting
A clinical trial investigating the safety and effectiveness of Smith and Nephew's FDA-approved Porous Total Knee System, which is used to replace worn away and diseased knee joints. The aim of this study is to show that most patients who receive the Porous Total Knee System have reduced pain, greater mobility and a long-lasting implant post-surgery.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/10/2023
Locations: Orthopaedic Specialists of Connecticut, Brookfield, Connecticut +23 locations
Conditions: Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
Male
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, plc., Lenexa, Kansas +2 locations
Conditions: Rheumatoid Arthritis
Register for Updates
COVID-19 VaccinE Response in Rheumatology Patients
NCT05080218
Recruiting
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prio... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Register for Updates